Daily Roundup | Anktiva Expands Bladder Cancer Label & Vanda's Anxiety Trial Misses

<p>FDA expanded ImmunityBio&#39;s Anktiva (nogapendekin alfa inbakicept-pmln) to papillary-only bladder cancer by extrapolating earlier evidence. Vanda paused VQW-765 after its Phase 3 social-anxiety trial missed, while Vir and Gilead agreed a solid-tumor T-cell engager collaboration. The roundup covers a European recommendation for Revolution Medicines&#39; daraxonrasib in pancreatic cancer, Osivax&#39;s OVX836 influenza-vaccine miss, and Alvotech/Advanz&#39;s AVT29 high-dose Eylea (aflibercept) biosimilar filing. Galderma&#39;s planned ZO Skin Health acquisition and OrbiMed&#39;s $3 billion in fund commitments round out the day.</p><p><br></p><p>Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.</p>